Although the deregulation of epidermal growth factor receptor (EGFR) is one of the most common molecular mechanisms of glioblastoma (GBM) pathogenesis, the efficacy of anti-EGFR therapy is limited. Additionally, response to anti-EGFR therapy is not solely dependent on EGFR expression and is more promising in patients with reduced activity of EGFR downstream signaling pathways. Thus, there is considerable interest in identifying the compensatory regulatory factors of the EGFR signaling pathway to improve the efficacy of anti-EGFR therapies for GBM. In this study, we confirmed the low efficacy of EGFR inhibitors in GBM patients by meta-analysis.
approximately 40-50% of primary GBM patients, and 60% of primary GBM patients have EGFR overexpression. 7, 10 Furthermore, EGFR overexpression has been implicated in the development and aggressiveness of GBM and found to be associated with unfavorable outcomes. 11, 12 This molecular characteristic of GBM makes it a compelling candidate for new therapeutic strategies.
In vitro, the genetic inhibition of EGFR expression can significantly attenuate the proliferation and invasion of GBM cells. 13, 14 Exogenous EGFR inhibitors can inhibit aberrant EGFR tyrosine kinase activity and selectively attenuate EGFR-mediated tumor invasion. 15, 16 However, the prognostic value of anti-EGFR treatment in GBM patients remains controversial because anti-EGFR therapies fail to decrease the activation of the downstream signaling molecules in EGFR pathways. 9, [17] [18] [19] [20] Moreover, the response to EGFR inhibitors is more marked in GBM patients with low levels of Akt phosphorylation. 21, 22 Thus, treatment of patients with erlotinib combined with PI3K/Akt pathway inhibitors could be highly beneficial. [23] [24] [25] Therefore, efforts to improve the efficacy of anti-EGFR treatments in GBM patients should focus on the activation of downstream pathways.
Connexin 43 (Cx43, encoded by the gap junction α 1 gene) is the most highly expressed isoform of the gap junction protein family in central nervous system tumors. 26, 27 Signals are transferred from adjacent tumor cells through gap junction intercellular communication mediated
by the channel structure of Cx43. 28, 29 In addition, Cx43 can interact with a large number of signaling and scaffolding proteins through its carboxy terminus (CT) to regulate the adhesion, migration, and proliferation of tumor cells. 30, 31 Both Akt and ERK have also been reported to bind and phosphorylate Cx43 CT, resulting in the closure of the hemichannels formed by Cx43. 32, 33 Of greater interest, the overexpression of Cx43 has been shown to inhibit the EGF-induced proliferation and invasion of different cancer cells. 34, 35 However, it is not clear whether Cx43
is involved in the regulation of the phosphorylation of Akt and ERK, the main downstream signaling effectors of EGFR.
In this study, we found that the expression level of Cx43 was negatively correlated with the activation of Akt/ERK in GBM patients with EGFR overexpression. Connexin 43 CT was found to directly interact with Akt and ERK1/2 to inhibit their hyperphosphorylation and to attenuate the activation of the epidermal growth factor (EGF)/EGFR signaling pathway. Truncated fragments containing specific residues successfully mimicked the interactions between Cx43 CT and Akt/ERK. Finally, Kaplan-Meier survival analysis showed a significant improved effect of Cx43 expression on the prognosis of GBM patients expressing EGFR.
| MATERIALS AND METHODS

| Cell lines, primary tumors cells, and glioma patient samples
The human GBM cell line U87 was purchased from ATCC (Rockefel- 
| Meta-analysis
We carried out this meta-analysis following the guidelines of the Meta-analysis of Observational Studies in Epidemiology group.
PubMed was systematically searched to identify relevant studies using the following keywords and their combination: "glioma," "EGFR," and "clinical trial." The combined hazard ratios (HRs) with their 95% confidence intervals (CIs) and P-values were determined using Stata data analysis and statistical software version 12.0 (Lakeway, TX, USA).
| Differentially expressed genes and gene set enrichment analysis
We undertook a gene set enrichment analysis (GSEA) using expression data derived from The Cancer Genome Atlas (TCGA) database. curves. In our study, the activated states of Akt and ERK were determined by the significant expression of their target gene sets.
By comparing the gene expression in response to activated and nonactivated Akt and ERK, we identified differentially expressed genes.
| Immunohistochemistry
Tumor samples from 23 glioma patients were immunohistochemically studied for the expression of Cx43, EGFR, phosphorylated (p-)Akt, and p-ERK. Briefly, tumor samples were prepared as previously described. 37 After an overnight incubation using antibodies against EGFR (1:100 dilution; Cell Signaling Technology, Boston, MA, USA), p-Akt (1:100 dilution; Cell Signaling Technology), p-ERK (1:100 dilution; Cell Signaling Technology), and Cx43 (1:100; Sigma, USA), the slides were incubated with secondary antibodies (Cell Signaling Technology). Immunostaining was carried out with the Envision System using diaminobenzidine (Dako, Denmark). The slides were counterstained with Mayer's hematoxylin, dehydrated, and mounted.
Finally, the results were analyzed by Image-Pro Plus 6.0 (Media Cybernetics, Inc., Rockville, MA, USA).
| Glioblastoma cell sphere culture and EGF treatment
Tumorspheres from U87 cells and primary specimens (GBM1, GBM2) were cultured as previously described. 36 The cells were starved for 24 h prior to treatment with recombinant human EGF (200 ng/mL; Sigma). Treatment with EGF for 30 min was carried out according to methods described in previous studies. 38 
| Plasmid constructs and transfection
The full-length cDNA of human Cx43 was a kind gift from the Han 
| Glutathione S-transferase pull-down assay
Glutathione S-transferase, or GST-bound Cx43 fragments, fusion proteins were generated using Escherichia coli BL21 (DE3) cells. The purification of GST-fused proteins for GST pull-down assays was carried out according to the instructions of the Pierce GST Protein Interaction 
| Survival analysis
For survival analysis, the expression data for 540 GBM patients were obtained from TCGA database (glioblastoma multiforme TCGA, provisional, http://www.cbioportal.org/). 39, 40 During the screening process, each patient was classified into a high or low expression group for any particular gene based on the cut-off value obtained from the corresponding receiver operating characteristic curve. Using data on OS and survival time, the Kaplan-Meier method was used to assess the association between the particular protein and the survival outcomes of GBM patients.
| Statistical analysis
Statistical analysis were under taken using SPSS version 16.0 software (SPSS, Chicago, IL, USA) and GraphPad Prism version 6.0 (GraphPad, San Diego, CA, USA). Student's t-test was used for comparisons between two groups. Survival analysis was carried out using the KaplanMeier method and the log-rank test. Correlations between the expression of Cx43 and p-Akt/p-ERK were assessed with Pearson's correlation analyses. P-values <0.05 were considered statistically significant.
| RESULTS
| Efficacy of anti-EGFR treatment is limited for GBM patients
As the efficacy of anti-EGFR treatment for GBM is controversial, 9, [17] [18] [19] [20] four studies involving a total of 367 GBM patients were included in this
primary meta-analysis to evaluate the prognostic role of anti-EGFR treatment in high-grade glioma. For studies evaluating OS, there was notable heterogeneity regarding anti-EGFR treatment. Hence, a random-effects model was used to calculate a pooled HR and its 95% CI. As shown in Figure 1 , meta-analysis of pooled HR and its 95% CI indicated a lack of significant difference (HR = 0.98; 95% CI, 0.76-1.27), implying that anti-EGFR treatment is not predictive of favorable outcomes.
| Expression of GJA1 is associated with suppression of Akt/ERK pathways
Previously, it was observed that the phosphorylation status of Akt/ ERK was independent of EGFR expression and could be considered a predictor of the efficacy of anti-EGFR treatment in glioma patients. 21, 41 To investigate this further, we identified GBM patients with EGFR amplification from TCGA database (Glioblastoma Multiforme TCGA, Provisional) (n = 223). We then obtained lists of differentially expressed genes, among which GJA1 encodes Cx43, the most abundant member of the gap junction protein family in the central nervous system, and reported to reduce EGF-induced proliferation in GBM and several cancer cells. 34, 35, 42 Thus, GSEA was carried out to determine the associations between GJA1 expression and the activation of EGFR downstream pathways. As shown in Figure 2A 
| Connexin 43 CT interacts with Akt and ERK
It has been observed that Cx43 can promote the phosphorylation of Akt and ERK between adjacent cells through its channel structuredependent function. [43] [44] [45] [46] However, here, we found that the phosphorylation of Akt and ERK was inhibited by Cx43 overexpression. Connexin 43 CT is known to interact with some kinases, such as SRC, to inhibit their phosphorylation. 47, 48 We also found that the high expres- 
| Connexin 43 expression improves the OS of EGFR-expressing GBM patients
Using Kaplan-Meier analysis and data from TCGA database (n = 540), we assessed the value of the combination of EGFR and Cx43 as prognostic biomarkers of GBM ( Figure 7) . Overall, patients with low EGFR levels had significantly longer OS than patients with high EGFR levels (P = 0.0009). However, in groups characterized by low Cx43 expression, patients with low EGFR levels had significantly better OS than patients with high EGFR levels (P = 0.0102). In contrast, in groups characterized by high Cx43 expression, there was no difference in OS between patients with low and high EGFR expression (P = 0.2379). When EGFR was non-amplified, the high amplification of Cx43 predicted a worse prognosis (Cx43 high vs. Cx43 low: 13.6 months vs. 15.1 months). However, when the EGFR pathway was activated by the amplification of EGFR, the high amplification of Cx43 brought a better prognosis (Cx43 high vs. Cx43 low, 13.9 months vs. 12.6 months), which indicated the inhibitory function exerted by Cx43 on the activation of the EGFR pathway. These 
| DISCUSSION
The persistent activation of Akt independent of EGFR has been a difficult problem during therapy using anti-EGFR agents and reduces the response to EGFR inhibitors in GBM patients. 21, 50, 51 In this study, we showed that Cx43 CT directly interacts with Akt and ERK to inhibit their hyperphosphorylation caused by the activation of EGFR. This inhibitory function of Cx43 CT represents a new molecular feature that could improve the prognosis of GBM patients with EGFR overexpression. These findings might also help us to improve the efficacy of anti-EGFR treatment in GBM patients.
Our findings are consistent with those of other studies, indicating that GBM patients not selected for any biological characteristic show modest response to EGFR inhibitors. [50] [51] [52] [53] The association of EGFR amplification with GBM tumors led to early optimism that EGFR inhibition would be beneficial. This initial optimism was mitigated, however, by the realization that only a subset of patients with EGFR-amplified GBM actually respond to EGFR blockade. 52, 53 Many researchers have observed that the efficacy of EGFR inhibitors in GBM is independent of EGFR amplification status. 21, 51 The failure of EGFR inhibitors in a majority of GBM patients with EGFR amplification could stem from inefficient blockade of the receptor or from the inability to reverse downstream signaling abnormalities associated with EGFR amplification. Actually, the therapeutic potential of Cx43 has attracted focus in recent years due to the Cx43-based tumor suppression of GBM cancer stem cells by reverting tumor cells to a normal phenotype. 62, 63 In addition to PEP-2, mentioned above, several mimic peptides have been produced to exert the tumor-suppressive function. Juxtamembrane 2 and α-connexin carboxyl-terminal 1, for example, were constructed to mimic the interaction between Cx43 with microtubules and ZO-1, respectively, which were proved to suppress tumor cells though inhibiting the epithelial-mesenchymal transition process. 64 However, the therapeutic potential could be limited because the F I G U R E 7 Expression of connexin 43 (Cx43) improves the overall survival of patients with epidermal growth factor receptor (EGFR)-expressing glioblastoma. Kaplan-Meier survival curves of overall survival duration were produced according to EGFR amplification and Cx43 expression in glioblastoma patients in The Cancer Genome Atlas cohort (n = 540). Statistical significance between two groups was evaluated using the log-rank test phenotype of tumor cells was not determined by Cx43 alone. Even Cx46, another subtype in the connexin family, played an essential role in CSC maintenance and GBM growth. 65 Most current pharmacological agents targeting Cx43 are non-specific and lack effect, making it difficult to ascribe the antitumor function to Cx43 alone. Thus, there is an undeniable need for more selective co-inhibitors or coactivators with Cx43 to exert a more defined action.
In summary, we report a novel finding that Cx43 can bind with Akt and ERK through its CT domain to inhibit EGF-induced phosphorylation of Akt and ERK. Thus, Cx43 could serve as a promising predictor for the efficacy of anti-EGFR treatment in GBM patients.
More importantly, the identification of specific interaction sites between Cx43 and Akt/ERK also implies an important therapeutic potential for synthesizing mimic peptides, although the current study did not define the specific sites on Akt or ERK1/2 that mediate their interactions with Cx43. 
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